13 completed, 1 active not recruiting, 1 recruiting. 8 Phase 2, 5 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 7, Active not recruiting 1 |
| Phase 3 | 5 | Completed 4, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
Follow ensifentrine: new trials by email Literature Review of ensifentrine trials Research Report on ensifentrine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) Ensifentrine, Placebo, Standard of Care (SOC) - Pulmonary Disease, Chronic Obstructive | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 2136 | 2026-11-02 | 2026-11-16 |
| A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 33 | 2025-10-06 | 2026-01-08 |
| Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 497 | 2025-07-31 | 2026-09-11 |
| Effect of Ensifentrine Treatment on CAT Score Ensifentrine 3 mg twice daily - COPD | Phase 3 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 20 | 2024-06-11 | 2025-04-18 |
| A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Ensifentrine, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Nuance Pharma (shanghai) Co., Ltd | 526 | 2023-03-10 | 2025-06-04 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects Ensifentrine - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Nuance Pharma (shanghai) Co., Ltd | 28 | 2023-03-06 | 2023-04-24 |
| Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) Ensifentrine, Placebo, LABA/LAMA - Pulmonary Disease, Chronic Obstructive, COPD | Phase 2 | Active not recruiting | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 70 | 2022-05-27 | 2026-11-03 |
| A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Ensifentrine, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 763 | 2020-09-29 | 2023-11-13 |
| A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Ensifentrine, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 790 | 2020-09-22 | 2023-10-16 |
| Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium - COPD | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 416 | 2019-05-01 | 2020-11-20 |
| A Study of RPL554 in Patients With Cystic Fibrosis RPL554, Placebo - Cystic Fibrosis | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 10 | 2017-02-08 | 2024-05-21 |
| The Effects of RPL554 in Addition to Tiotropium in COPD Patients 1.5 mg RPL554 plus tiotropium, 6 mg RPL554 plus tiotropium, Placebo plus tiotropium - Chronic Obstructive Pulmonary Disease Moderate | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 30 | 2017-01-01 | 2019-02-27 |
| The Effects of RPL554 on Top of Standard COPD Reliever Medications Salbutamol, Ipratropium, RPL554 - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 36 | 2015-10-01 | 2016-09-09 |
| Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients RPL554, Salbutamol, Placebo - Asthma | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 29 | 2015-04-01 | 2016-09-09 |
| SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects RPL554, Placebo - Inflammatory Disorder of the Respiratory Tract, Chronic Obstructive Pulmonary Disorder | Phase 1 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 112 | 2014-12-01 | 2015-10-28 |
Pulmonary Disease, Chronic Obstructive (12) · Asthma (1) · Cystic Fibrosis (1) · Lung Diseases (1)
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (12) · Nuance Pharma (shanghai) Co., Ltd (2) · Merck Sharp & Dohme LLC (1)
United States (8) · United Kingdom (5) · Bulgaria (2) · China (2) · Hungary (2) · Poland (2) · Slovakia (2) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · Estonia (1) · Germany (1) · Greece (1) · Romania (1)
Dave Singh (2) · Andres Floto (1) · Gary Ferguson (1) · Johnston Stewart (1) · Lief Bjermer (1)
PMID 30166326, PMID 37364283, PMID 39106052, PMID 39197510, PMID 39854278, PMID 31202957, PMID 41710324, PMID 41895581
2015 (2)